$0.37
4.49%
Nasdaq, Sep 02, 09:55 pm CET
ISIN
US92243A2006
Symbol
VXRT

Vaxart, Inc. Stock price

$0.38
+0.01 2.33% 1M
-0.09 19.84% 6M
-0.28 42.83% YTD
-0.49 56.34% 1Y
-2.47 86.72% 3Y
-5.14 93.14% 5Y
-23.38 98.41% 10Y
-331.25 99.89% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
-0.01 2.95%
ISIN
US92243A2006
Symbol
VXRT
Industry

Key metrics

Basic
Market capitalization
$86.7m
Enterprise Value
$48.5m
Net debt
positive
Cash
$41.9m
Shares outstanding
228.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.8 | 1.4
EV/Sales
1.0 | 0.8
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
35.4%
Return on Equity
-113.6%
ROCE
-95.2%
ROIC
-169.2%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$47.4m | $63.0m
EBITDA
$-48.2m | -
EBIT
$-57.2m | $-71.9m
Net Income
$-58.1m | $-65.3m
Free Cash Flow
$-33.7m
Growth (TTM | estimate)
Revenue
433.2% | 119.4%
EBITDA
34.0% | -
EBIT
30.2% | -8.5%
Net Income
28.9% | 2.4%
Free Cash Flow
50.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-101.8% | -
EBIT
-120.6%
Net
-122.6% | -103.8%
Free Cash Flow
-71.2%
More
EPS
$-0.3
FCF per Share
$-0.1
Short interest
9.4%
Employees
105
Rev per Employee
$270.0k
Show more

Is Vaxart, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Vaxart, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vaxart, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Vaxart, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Vaxart, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
47 47
433% 433%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
20% 20%
39%
- Research and Development Expense 86 86
27% 27%
181%
-48 -48
34% 34%
-102%
- Depreciation and Amortization 8.92 8.92
2% 2%
19%
EBIT (Operating Income) EBIT -57 -57
30% 30%
-121%
Net Profit -58 -58
29% 29%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about Vaxart, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxart, Inc. Stock News

Neutral
GlobeNewsWire
about 10 hours ago
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science a...
Neutral
GlobeNewsWire
about 18 hours ago
Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Stockholder Opposition Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Stockholder Opposition
Neutral
GlobeNewsWire
13 days ago
Urge Stockholders to Vote “AGAINST” Reverse Stock Split at Upcoming Special Meeting Call for Accountability Given Board's Pattern of Disregarding Stockholders' Will and Value-Destructive Capital Allocation Decisions ATLANTA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew M.
More Vaxart, Inc. News

Company Profile

Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.

Head office United States
CEO Steven Lo
Employees 105
Founded 2004
Website vaxart.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today